Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Dr. Mobasher - Synopsis below extracted from the video transcript.
Dr. Mehrdad Mobasher, an oncologist and public health expert, presented the findings of a clinical trial comparing zanubrutinib to ibrutinib in treating relapsed or refractory CLL and SLL (SLL).
Dr. Mobasher says both BTK inhibitors target a B-cell receptor signaling pathway and cure CLL and SLL. Zanubrutinib, a second-generation BTK inhibitor, is more selective and less off-target than ibrutinib.
The trial comprised 201 previously treated relapsed or refractory CLL or SLL patients. Randomly assigned zanubrutinib or ibrutinib. ORR, PFS, OS, and safety were the trial's primary and secondary goals.
Zanubrutinib outperformed ibrutinib in ORR (94.9% vs. 84.8%) and PFS (median not reached vs. 28.3 months). They share OS. Zanubrutinib caused less atrial fibrillation and bleeding than ibrutinib.
Read The Full Transcript and Watch The Video Here
These findings affect CLL and SLL therapy, especially for relapsed or refractory patients, according to Dr. Mobasher. He emphasizes patient, condition, and treatment history-based personalized therapy. He urges continuing research to identify new medicines and improve patient outcomes.
The movie addresses BTK inhibitor treatment advances and the potential benefits of zanubrutinib over ibrutinib in CLL and SLL patients. The video educates healthcare professionals, researchers, and cancer aficionados.
